Research programme: lysosphingolipid receptor agonists - Amgen/EPIX

Drug Profile

Research programme: lysosphingolipid receptor agonists - Amgen/EPIX

Alternative Names: AMG 277; PRX-13038; S1P1 agonists - EPIX

Latest Information Update: 07 Oct 2011

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer Amgen; EPIX Pharmaceuticals
  • Class
  • Mechanism of Action Lysosphingolipid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer

Most Recent Events

  • 06 Oct 2011 This programme will be offered for sale on December 8, 2011 ,,
  • 01 Oct 2009 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
  • 28 Mar 2008 Research programme is still in preclinical trials for Autoimmune disorders in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top